for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genmab A/S

GMAB.CO

Latest Trade

2,293.00DKK

Change

-6.00(-0.26%)

Volume

19,660

Today's Range

2,278.00

 - 

2,309.00

52 Week Range

1,082.50

 - 

2,368.00

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,299.00
Open
2,300.00
Volume
19,660
3M AVG Volume
4.99
Today's High
2,309.00
Today's Low
2,278.00
52 Week High
2,368.00
52 Week Low
1,082.50
Shares Out (MIL)
65.20
Market Cap (MIL)
150,231.80
Forward P/E
30.96
Dividend (Yield %)
--

Next Event

Q2 2020 Genmab A/S Earnings Release

Latest Developments

More

Genmab Reports Net Sales Of Darzalex In Q2 2020 Totaled $901 Mln

Genmab Q2 Net Sales Of Darzalex At USD 901 Mln

Genmab Announces Very Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genmab A/S

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Industry

Biotechnology & Drugs

Contact Info

Kalvebod Brygge 43

1560

Denmark

+45.null.70202728

http://www.genmab.com

Executive Leadership

Deirdre P. Connelly

Chairman of the Board

Jan G. J. van de Winkel

President and Chief Executive Officer

Anthony Pagano

Chief Financial Officer, Executive Vice President

Anthony Mancini

Chief Operating Officer, Executive Vice President

Judith Klimovsky

Executive Vice President, Chief Development Officer

Key Stats

2.32 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2017

2.4K

2018

3.0K

2019

5.4K

2020(E)

9.6K
EPS (DKK)

2017

17.770

2018

23.730

2019

34.030

2020(E)

72.744
Price To Earnings (TTM)
63.67
Price To Sales (TTM)
26.51
Price To Book (MRQ)
10.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.21
LT Debt To Equity (MRQ)
1.03
Return on Investment (TTM)
20.67
Return on Equity (TTM)
19.66

Latest News

Latest News

BRIEF-Genmab Announces Very Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

* GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

BRIEF-Genmab Announces Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

* REG-GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

Abbvie to partner with Denmark's Genmab in $750 million cancer therapy deal

Abbvie Inc <ABBV.N> said on Wednesday it is partnering with Danish biotech firm Genmab AS <GMAB.CO> to jointly develop and market cancer treatments, as it looks to expand its cancer franchise.

Abbvie partners with Genmab in $750 mln cancer therapy deal

Abbvie Inc said on Wednesday it has entered into an agreement with Genmab AS to jointly develop and commercialize cancer treatment.

BRIEF-Genmab And AbbVie Announce Broad Oncology Collaboration

* REG-GENMAB AND ABBVIE ANNOUNCE BROAD ONCOLOGY COLLABORATION

BRIEF-Genmab Announces European Marketing Authorization For Subcutaneous Formulation Of Darzalex®

* REG-GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR THE SUBCUTANEOUS FORMULATION OF DARZALEX® (DARATUMUMAB) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

BRIEF-Genmab -U.S.FDA Extends Review

* REG-U.S. FDA EXTENDS REVIEW OF SBLA, SUBMITTED BY NOVARTIS, FOR OFATUMUMAB IN RELAPSING MULTIPLE SCLEROSIS

BRIEF-Genmab Says Positive Topline Results In Phase III Andromeda Study Of Daratumumab In Light-Chain (AL) Amyloidosis

* REG-GENMAB ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN LIGHT-CHAIN (AL) AMYLOIDOSIS

BRIEF-Tavotek Biotherapeutics Enters Into Research Agreement With Genmab A/S To Develop Bispecific Antibodies

* TAVOTEK BIOTHERAPEUTICS - ENTERED INTO RESEARCH AGREEMENT WITH GENMAB A/S TO DEVELOP BISPECIFIC ANTIBODIES USING GENMAB'S DUOBODY TECHNOLOGY PLATFORM Source text for Eikon: Further company coverage:

BRIEF-Genmab Q1 Operating Result Swings To Profit DKK 71 Mln

* REG-GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020

BRIEF-Genmab Announces U.S. FDA Approval Of Subcutaneous Formulation Of Daratumumab, Darzalex Faspro For The Treatment Of Patients With Multiple Myeloma

* GENMAB ANNOUNCES U.S. FDA APPROVAL OF SUBCUTANEOUS FORMULATION OF DARATUMUMAB, DARZALEX FASPRO™ (DARATUMUMAB AND HYALURONIDASE-FIHJ), FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

BRIEF-Genmab Says CHMP Issues Positive Opinion Recommending Subcutaneous Formulation Of Daratumumab For The Treatment Of Patients With Multiple Myeloma

* REG-CHMP ISSUES POSITIVE OPINION RECOMMENDING SUBCUTANEOUS FORMULATION OF DARATUMUMAB FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

BRIEF-Genmab Q1 Net Sales Of Darzalex USD 937 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2020

BRIEF-Genmab: FDA Accepts sBLA Submitted By Novartis

* REG-U.S. FDA FILING ACCEPTANCE AND PRIORITY REVIEW FOR SBLA, SUBMITTED BY NOVARTIS, FOR OFATUMUMAB IN RELAPSING MULTIPLE SCLEROSIS

BRIEF-Genmab Board Of Directors Chairman Mats Pettersson To Step Down

* GENMAB - CHAIRMAN OF BOARD MATS PETTERSSON DECIDED TO STEP DOWN FROM BOARD AT CO'S ANNUAL GENERAL MEETING ON MARCH 26, 2020

BRIEF-Genmab FY EBIT At DKK 2.64 Bilion

* 2020 OUTLOOK: WE EXPECT OUR 2020 REVENUE TO BE IN RANGE OF DKK 4,750 - 5,150 MILLION, COMPARED TO DKK 5,366 MILLION IN 2019.

BRIEF-Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

* SAYS IBEX SOLUTIONS TO SUPPORT GENMAB’S GROWING CLINICAL PORTFOLIO

BRIEF-Genmab: Partner For Ofatumumab Presents Positive Results From Phase III Asclepios I, II Studies

* DETAILED RESULTS FROM PHASE III ASCLEPIOS I & II STUDIES OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS PRESENTED AT ECTRIMS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up